Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00937716 · ClinicalTrials.gov registry record
Treatment Response in Schizophrenia: Bridging Imaging and Postmortem Studies
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 75
- Enrollment target
NCT00937716: Completed study, sponsored by University of Alabama at Birmingham.
NCT00937716 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 75 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00937716 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 75 participants
- Enrollment target
Study Summary
The overarching goal is to identify imaging markers that will predict treatment response, and to confirm or validate these biomarkers using anatomical studies of postmortem tissue. Early detection of drug response would yield specific treatment strategies that are tailored to the individual, thus improving both the quality of life of the patients and drastically reducing the costs associated with unsuccessful treatment strategies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2008-10 |
| Est. Completion | 2021-06-30 |
What the finished NCT00937716 record still lists
NCT00937716 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 75 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00937716 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00937716 about?
NCT00937716 is a clinical study titled "Treatment Response in Schizophrenia: Bridging Imaging and Postmortem Studies". The overarching goal is to identify imaging markers that will predict treatment response, and to confirm or validate these biomarkers using anatomical studies of postmortem tissue. Early detection of drug response would yield specific treatment strategies that are tailored to the individual, thus im...
What is the current status of trial NCT00937716?
This trial is currently completed. The enrollment target is 75 participants. The study started on 2008-10. Estimated completion is 2021-06-30.
Who is sponsoring clinical trial NCT00937716?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia